CV Sciences Stock-Based Compensation Growth & History (CVSI)
CV Sciences's stock-based compensation was $497,000 for fiscal 2025.
View full CV Sciences company overviewCV Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $497,000 | $239,000 | +92.64% |
| 2024 | 2024-12-31 | $258,000 | $40,000 | +18.35% |
| 2023 | 2023-12-31 | $218,000 | −$791,000 | −78.39% |
| 2022 | 2022-12-31 | $1.0M | −$2.2M | −68.57% |
| 2021 | 2021-12-31 | $3.2M | −$671,000 | −17.29% |
| 2020 | 2020-12-31 | $3.9M | −$1.7M | −30.56% |
| 2019 | 2019-12-31 | $5.6M | $2.7M | +91.08% |
| 2018 | 2018-12-31 | $2.9M | −$494,000 | −14.45% |
| 2017 | 2017-12-31 | $3.4M | $686,092 | +25.10% |
| 2016 | 2016-12-31 | $2.7M | −$3.0M | −52.22% |
| 2015 | 2015-12-31 | $5.7M | −$2.2M | −27.74% |
| 2014 | 2014-12-31 | $7.9M | $7.9M | — |
| 2013 | 2013-12-31 | $0 | — | — |
CV Sciences quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $148,000 | $16,000 | +12.12% |
| Q1 2026 | 2026-03-31 | $148,000 | $30,000 | +25.42% |
| Q4 2025 | 2025-12-31 | $123,000 | $19,000 | +18.27% |
| Q3 2025 | 2025-09-30 | $124,000 | $37,000 | +42.53% |
| Q2 2025 | 2025-06-30 | $132,000 | $95,000 | +256.76% |
| Q1 2025 | 2025-03-31 | $118,000 | $88,000 | +293.33% |
| Q4 2024 | 2024-12-31 | $104,000 | $71,000 | +215.15% |
| Q3 2024 | 2024-09-30 | $87,000 | $55,000 | +171.88% |
| Q2 2024 | 2024-06-30 | $37,000 | $2,000 | +5.71% |
| Q1 2024 | 2024-03-31 | $30,000 | −$88,000 | −74.58% |
| Q4 2023 | 2023-12-31 | $33,000 | −$137,000 | −80.59% |
| Q3 2023 | 2023-09-30 | $32,000 | −$145,000 | −81.92% |
| Q2 2023 | 2023-06-30 | $35,000 | −$111,000 | −76.03% |
| Q1 2023 | 2023-03-31 | $118,000 | −$398,000 | −77.13% |
| Q4 2022 | 2022-12-31 | $170,000 | −$665,000 | −79.64% |
| Q3 2022 | 2022-09-30 | $177,000 | −$629,000 | −78.04% |
| Q2 2022 | 2022-06-30 | $146,000 | −$766,000 | −83.99% |
| Q1 2022 | 2022-03-31 | $516,000 | −$141,000 | −21.46% |
| Q4 2021 | 2021-12-31 | $835,000 | $70,000 | +9.15% |
| Q3 2021 | 2021-09-30 | $806,000 | $191,000 | +31.06% |
| Q2 2021 | 2021-06-30 | $912,000 | −$331,000 | −26.63% |
| Q1 2021 | 2021-03-31 | $657,000 | −$601,000 | −47.77% |
| Q4 2020 | 2020-12-31 | $765,000 | $91,000 | +13.50% |
| Q3 2020 | 2020-09-30 | $615,000 | −$84,000 | −12.02% |
| Q2 2020 | 2020-06-30 | $1.2M | −$882,000 | −41.51% |
| Q1 2020 | 2020-03-31 | $1.3M | −$833,000 | −39.84% |
| Q4 2019 | 2019-12-31 | $674,000 | −$617,000 | −47.79% |
| Q3 2019 | 2019-09-30 | $699,000 | $461,000 | +193.70% |
| Q2 2019 | 2019-06-30 | $2.1M | $1.8M | +490.28% |
| Q1 2019 | 2019-03-31 | $2.1M | $1.1M | +101.83% |
| Q4 2018 | 2018-12-31 | $1.3M | $944,224 | +272.29% |
| Q3 2018 | 2018-09-30 | $238,000 | −$1.1M | −82.08% |
| Q2 2018 | 2018-06-30 | $360,000 | −$197,837 | −35.47% |
| Q1 2018 | 2018-03-31 | $1.0M | −$150,291 | −12.67% |
| Q4 2017 | 2017-12-31 | $346,776 | −$1.0M | −74.78% |
| Q3 2017 | 2017-09-30 | $1.3M | $788,120 | +145.95% |
| Q2 2017 | 2017-06-30 | $557,837 | $145,280 | +35.21% |
| Q1 2017 | 2017-03-31 | $1.2M | $781,140 | +192.80% |
| Q4 2016 | 2016-12-31 | $1.4M | −$246,475 | −15.20% |
| Q3 2016 | 2016-09-30 | $539,976 | −$1.2M | −69.21% |
| Q2 2016 | 2016-06-30 | $412,557 | −$175,735 | −29.87% |
| Q1 2016 | 2016-03-31 | $405,151 | −$1.4M | −76.93% |
| Q4 2015 | 2015-12-31 | $1.6M | −$6.3M | −79.51% |
| Q3 2015 | 2015-09-30 | $1.8M | $1.8M | — |
| Q2 2015 | 2015-06-30 | $588,292 | $588,292 | — |
| Q1 2015 | 2015-03-31 | $1.8M | $1.8M | — |
| Q4 2014 | 2014-12-31 | $7.9M | — | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
| Q2 2014 | 2014-06-30 | $0 | — | — |
| Q1 2014 | 2014-03-31 | $0 | — | — |
CV Sciences stock-based compensation trends
Over the last five fiscal years, CV Sciences's stock-based compensation decreased from $3.9M to $497,000, a change of −$3.4M. The latest reported quarter, Q2 2026, shows $148,000.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CV Sciences source filings ↗